Regeneron (REGN) – Reuters
-
US accuses Regeneron of fraudulent price reporting for eye drug
-
Regeneron's blood cancer therapy faces setback as FDA raises trial concerns
-
Regeneron beats fourth-quarter revenue estimates
-
Regeneron preliminary Q4 US sales of Eylea below expectations
-
Regeneron sees strong initial demand for higher-dose Eylea
-
US FDA approves Regeneron's ultra-rare blood disease drug
-
US FDA declines to approve Regeneron's higher-dose Eylea, shares tumble
-
Regeneron's Eylea drug sales hit by competition from 'new kid in town'
-
US FDA expands use of Regeneron's cholesterol drug in young children
-
Regeneron profit beats estimates on Dupixent strength
-
Regeneron revenue beats estimates on strong sales of Eylea, COVID therapy
-
Regeneron's COVID-19 antibody drug may be less effective against Omicron
-
Regeneron's antibody drug shows protection against COVID-19 for up to 8 months
-
Regeneron beats quarterly sales on COVID-19 drug demand
-
Regeneron sees uptick in COVID-19 therapy use as cases rise
-
EU regulator advises use of Regeneron antibody cocktail for COVID-19
-
Regeneron says Roche successfully tested manufacture of COVID-19 drug used on Trump
-
Tech, health stocks rise, cyclicals fall on prospects of divided U.S. Congress
-
U.S. strikes deal with Lilly for potential COVID-19 antibody drug
-
Eli Lilly strikes optimistic tone on COVID-19 therapy after trial failure
-
Exclusive: FDA faults quality control at Lilly plant making Trump-touted COVID drug
-
U.S. pauses Eli Lilly trial of antibody drug Trump touted as COVID-19 'cure' over safety concern
-
Fauci says 'reasonably good chance' Regeneron antibody therapy helped Trump
-
Wall Street gains as Trump to leave hospital, investors hope for stimulus
-
Regeneron says its COVID-19 treatment reduces viral levels, improves symptoms
-
AstraZeneca starts trial of COVID-19 antibody treatment
-
Roche, Regeneron link up to develop COVID-19 antibody cocktail
-
Big Tech drives S&P 500 to record high in coronavirus rally
-
Teva Pharm second-quarter profit tops forecast, reaffirms 2020 outlook
-
Eli Lilly tests antibody drug to halt COVID-19 spread in U.S. nursing homes
-
U.S. signs $450 million contract with Regeneron for COVID-19 therapy
-
Sanofi clinches $2 billion vaccines deal with Translate Bio
-
U.S. companies issue shares at fastest rate ever, selling the rally
-
Drugmaker Sanofi to raise over $11 billion via sale of Regeneron shares
-
Sanofi shares down despite $13 billion Regeneron payday
-
Wall Street rises as lockdowns ease, healthcare shares jump
-
Investors await data on coronavirus drugs as market rally builds
-
Wall Street jumps after Monday's historic sell-off as Fed boosts liquidity to fight coronavirus effect
-
Drugmaker Sanofi expects further profit growth from narrowed focus
-
Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker
-
Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
-
Express Scripts targets Amgen, Lilly migraine drugs in pricing shift
-
S&P keeps New Year's rally alive, Dow eases
-
Sanofi pegs U.S. drug price rises to below healthcare inflation
-
Regeneron shares poised for rebound: Barron's
-
Boosted by Apple, Wall Street parties like it's 19,999
-
Tech, bank shares slip after recent gains; health outperforms
-
Janus portfolio manager sees more biotech gains on Trump
-
S&P 500 losing streak extends to ninth straight day
-
Pfizer cholesterol drug fizzles, hitting shares
Back to REGN Stock Lookup
